Measles, mumps and rubella outbreaks still represent an healthcare issue, even though major advancements have been done towards their eradication. A poor inclination towards Mmr (measles-mumps-rubella) vaccination may constitute a major cause of increased risk to contract one of these diseases amongst specific population groups like migrants, alternative medicine users, some religious groups, healthcare professionals.
Information on Mmr vaccines coverage amongst these and others “hard-to-reach” groups was included in a document made and published Ecdc in range of the European project Venice II (Vaccine European New Integrated Collaboration Effort II). Main aim of the document was to provide a complete review of measles, mumps and rubella focuses which have been reported in the last twenty years in Europe.
An update on Mmr
Primary tabs
Autori:
Sezioni:
Indice:
Vaccination
prossimo articolo
A tour through European scientific governance
European research is fundamental for guaranteeing future competitiveness to our economies, as acknowledged by all EU member States that committed to reach investments in research and development equal to 3% of GDP. Up to date, however, the funds allocated by the 28 Countries of the Union remain below the 2% of GDP and on average do not exceed 0.7% (Fig. 1). Some Nations, however, are reversing their route. In 2000, Germany and France presented similar balance sheets; ten years later, Germany remains the only country that constantly increased public funds.